Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by three referees whose comments are shown below.
As you will see from the reports all three referees express interest in the findings reported in your manuscript and highlight the potential impact in the pain field. However, at the same time they also raise a number of experimental concerns that will have to be addressed in full before they can support publication in The EMBO Journal. Most importantly, refs #1 and #2, while being overall largely positive about the study, ask for additional data on the available ASIC3 knockout mouse to be included. In addition to that, ref#3 has more extensive concerns about the specificity of the effects reports here, both with regard to the activated channel and to the nature of the agonist.
We realize that addressing all points raised by the referees will involve extensive additional work of uncertain outcome, but should you be able to provide this data we would consider a revised manuscript. I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses in this revised version. If you decide to thoroughly revise the manuscript for the EMBO Journal, please include a detailed point-by-point response to the referees' comments. Please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.embo.org/embo-press We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
REFEREE REPORTS
Referee #1:
The work done by Marra and colleagues reveals a group of non-acidic activators of ASIC3, an important acid-sensing ion channel involved in nociception and many non-nociceptive sensory functions. The authors first identified high levels of LPC and arachidonic acid in non-acidic joint exudates from 2 patients with painful arthritis. Then, the authors conducted a series of elegant in vitro studies to show LPC 16:0 and 18:1 selectively activates human and rat ASIC3 but not other ASIC subtypes. Finally, an ex vivo recording on skin-nerve preparation was used to confirm the effect of LPC/AA on amiloride-sensitive C fibers and LPC was also found inducing flinches behaviors in vivo, when subcutaneously injected into a rat hind paw. In general, the work is novel and will have great impact on pain biology and new analgesic drug development. The paper is well written, the result finding is novel and interesting, the discussion is balanced and appropriate, and the conclusion is exciting. Beneath are some minor comments for the exciting manuscript.
1. So far, there is no ASIC3 agonist available for exploring the role of ASIC3 in vivo. As mentioned, the GMQ/agmatine is not selective enough to activate ASIC3. Thus, the identification of a selective ASIC3 activator is very exciting and very much appreciated.
2. Do LPE, LPS, LPI, LPA activate an ASIC3 current at pH7.4? 3. Are high levels of LPC also existed in most patients with painful arthritis and acidic joint exudates?
4. Figure 2D . What is the Icontrol? 5. Figure 2D . Please comment why there was no does-dependent effect of LPC on rat ASIC3. The result looks like an all-or-none effect.
6. In Figure 6B , are small diameter DRG neurons selectively used in this study? If so, what was the size range to define the small-diameter DRG neurons? If not, what neural populations were recorded?
7. Figure 6C . The LPC/AA-induced enhancement of AP firing can be prevented by amiloride, suggesting an involvement of ASIC activation. However, the data cannot fully support this is totally contributed by ASIC3.
8. Figure 6D . The vehicle seems to induce some flinching responses. Why? Usually, rodents do not have many flinches after receive a needle penetration. The author's previous work showed only ~2 flinches in vehicle group (Deval et al., EMBO J 27: 3047-3055, 2008) . 9. Although APETx2 was used to show the specific effect of LPC/AA on ASIC3 in data of Figure 6 . A recent paper also shows that high concentrations of APETx2 inhibit Nav1.8. These results would be more convincing if they are conducted in ASIC3 knockout mice.
Referee #2:
This is a potentially very important paper. It changes the whole perspective on the function of ASICS. Just as thermoTRPs are not temperature sensors in vivo, it seems ASICs are not acid sensing physiologically. This is very interesting work. That said, why the authors have not used available ASIC3 KO mice to test the effects of their lipid activators is baffling. With this additional information the paper would be very strong. Some small errors -for example abstract line 1 -triggers.
Referee #3:
Marra et al report that inflammatory exudates of two patients with joint effusions activated at neutral pH ASIC3 channels expressed in HEK 293 cells. This is potentially an important observation related to pain sensation. Analysis of the total fatty acid content of the patients' exudates indicated high levels of arachidonic acid (AA) and lysophosphatidylcholine (LPC). Application of both fatty acids to ASIC3 channels activates ASIC3 channels at neutral pH. Similarly, AA and LPC evoke a robust Na+ inward current in DRG neurons and increase firing of nociceptive C-fibers. Therefore, Marra et al propose that ASIC3 channels, in addition to acid-sensing, play an important role in lipid-mediated inflammatory responses.
There are several queries concerning the data presented:
The patients' exudates appear to specifically activate ASIC3 channels, but not ASIC1a channels. AA and LPC seem to affect the activity of many channels. Previously published data indicated that AA and LPC effects are not specific for ASIC3 channels (e.g. Smith et al, 2007) . It should be demonstrated that the data shown in Figs. 2 ff are specific for ASIC3 channels. If not, the exudates may contain another substance functioning as an ASIC channel agonist. Considering the data in Previously it was shown that alkalization (a shift from pH 7 to pH 8) evokes a sustained ASIC3 current. Two arginines are involved in this response. Are the same arginines involved in the AA/LPC response?
The AA/LPC binding site(s) should be defined and compared with those for APETx2 and the pH sensor.
Previous data showed that AA acts on ASIC channel from both sides of the membrane. In contrast, LPC seems to activate ASIC3 channel only from the outside of the membrane. This important difference should be discussed.
In summary, arachidonic acid has been shown to affect many different ion channels. This may be due to indirect effects on cellular metabolism, protein kinase activities, changes in membrane curvature, and so on. A direct effect of lipid by binding to a site(s) on the channel needs to be shown unequivocally. The results reported in this study are potentially of great physiological relevance, especially in pain research. However, there are too many questions left which need to be answered before the ms may be acceptable for publication. Referee #1:
The work done by Marra and colleagues reveals a group of non-acidic activators of ASIC3, an important acid-sensing ion channel involved in nociception and many non-nociceptive sensory functions. The authors first identified high levels of LPC and arachidonic acid in non-acidic joint exudates from 2 patients with painful arthritis. Then, the authors conducted a series of elegant in vitro studies to show LPC 16:0 and 18:1 selectively activates human and rat ASIC3 but not other ASIC subtypes. Finally, an ex vivo recording on skin-nerve preparation was used to confirm the effect of LPC/AA on amiloride-sensitive C fibers and LPC was also found inducing flinches behaviors in vivo, when subcutaneously injected into a rat hind paw. In general, the work is novel and will have great impact on pain biology and new analgesic drug development. The paper is well written, the result finding is novel and interesting, the discussion is balanced and appropriate, and the conclusion is exciting.
Beneath are some minor comments for the exciting manuscript.
2. Do LPE, LPS, LPI, LPA activate an ASIC3 current at pH7.4? => We have performed new patch clamp experiments in order to test the potential activating effects of LPE, LPS, LPI and LPA on ASIC3 channel at pH 7.4. We now show that LPC is the only lysophospholipid able to activate a constitutive ASIC3 current at resting pH7.4 (see new Fig. 2E and results page 7). We have also included new data showing that phosphatidylcholine (PC) containing both palmitic and arachidonic acid (PC 16:0/20:4) had no effect at pH 7.4 (see new Fig.  2B and results page 7), which reinforces the specificity of LPC towards ASIC3 channels.
3. Are high levels of LPC also existed in most patients with painful arthritis and acidic joint exudates?
=> We are now showing data on exudates collected from 11 different patients (see new Fig.  EV1) . Most of the patients were painful but interestingly none of the exudates were acidic (i.e., with pH≥7.4). Two of these exudates have physiologically neutral pH (with values close to 7.4, ex#2 and ex#13), while the others have pH with values ranging between 7.6 and 7.9. We have analyzed the LPC content of all these exudates, which show high levels of LPC and especially LPC 16:0 regardless of their etiologies (see new Figs. 1G and EV1 and results page 6). The levels of LPC (> 20 µM) are always compatible with the concentration needed to activate ASIC3 at pH 7.4 (> 1 µM). However, it is not possible, from the limited number of patients studied here, to correlate the estimated LPC concentrations with pain assessed with visual analog scale (VAS).
4. Figure 2D . What is the Icontrol? Icontrol represented the basal current level at pH7.4 before the application of LPC. To avoid any misunderstanding on Figure 2D , and to better represent the concentration dependence of the activating effect of LPC, we performed additional experiments and modified the figure, which now shows the mean ASIC3 current densities generated by different concentrations of LPC (see new Fig. 2D , and see also point n°5).
5. Figure 2D . Please comment why there was no does-dependent effect of LPC on rat ASIC3. The result looks like an all-or-none effect.
==> This was mainly due to the high variability of the activating effect observed with 3 µM LPC. We have therefore done new experiments (n=8-16) with addition of an intermediate LPC concentration at 5µM to refine the dose-response effect. Based on the data shown in new Figure 2D , we are now able to estimate the EC 50 for the activation of ASIC3 by LPC at resting pH7.4 (4.3µM; see results page 7).
6. In Figure 6B, 7. Figure 6C . The LPC/AA-induced enhancement of AP firing can be prevented by amiloride, suggesting an involvement of ASIC activation. However, the data cannot fully support this is totally contributed by ASIC3.
==> We agree with the reviewer that the effect of amiloride on AP firing strongly suggests an involvement of ASIC channels but is not sufficient to entirely support the contribution of ASIC3. However, in vivo experiments showing inhibition of lipid-evoked pain in rats by amiloride or APETx2, combined with new data demonstrating that the lipid-induced pain in mice is significantly reduced in ASIC3 knockout animals (see new Fig. 6E and point n°9 below) both fully support the specific contribution of ASIC3 in lipid-evoked pain.
8. Figure 6D . The vehicle seems to induce some flinching responses. Why? Usually, rodents do not have many flinches after receive a needle penetration. The author's previous work showed only ~2 flinches in vehicle group (Deval et al., EMBO J 27: 3047-3055, 2008) .
==> As noted by the reviewer, we observed a flinching response when animals were injected with vehicle only (20 ± 5 flinches over a period of 20 min, see Fig. 6D ). This is due to the presence of ethanol (0.24%) in the vehicle, which was not the case in our previous work where vehicle was only saline solution (Deval et al., EMBO J. 2008). The "Material and Methods" section (page 21) have been slightly modified to make it clearer. 9. Although APETx2 was used to show the specific effect of LPC/AA on ASIC3 in data of Figure 6 . A recent paper also shows that high concentrations of APETx2 inhibit Nav1.8. These results would be more convincing if they are conducted in ASIC3 knockout mice.
==> We are now providing new data obtained in mice, showing that subcutaneous injections of lipids (LPC16:0 + AA) into animal hindpaws induce a significant pain behavior in wild-type mice that is significantly reduced in ASIC3 knockout mice (see new Fig. 6E and results page 12).
Referee #2:
This is a potentially very important paper. It changes the whole perspective on the function of ASICS. Just as thermoTRPs are not temperature sensors in vivo, it seems ASICs are not acid sensing physiologically. This is very interesting work. That said, why the authors have not used available ASIC3 KO mice to test the effects of their lipid activators is baffling. With this additional information the paper would be very strong.
==> As suggested by the reviewer, we performed additional experiments in ASIC3 knockout mice. We now show that subcutaneous injections of lipids (LPC16:0 + AA) into the mouse hindpaw induces a significant pain behavior in wild-type animals that is significantly reduced in ASIC3 knockout mice (see new Fig. 6E and results page 12).
Some small errors -for example abstract line 1 -triggers.
==> Errors have been corrected as far as possible.
Referee #3:
The patients' exudates appear to specifically activate ASIC3 channels, but not ASIC1a channels. AA and LPC seem to affect the activity of many channels. Previously published data indicated that AA and LPC effects are not specific for ASIC3 channels (e.g. Smith et al, 2007) . It should be demonstrated that the data shown in Figs. 2 are specific for ASIC3 channels. If not, the exudates may contain another substance functioning as an ASIC channel agonist. Considering the data in Fig.  5 , specificity is potentially restricted to LPC. ==> Smith et al. (Neuroscience 2007,145, 686-698) showed that AA is able to potentiate the acid-induced current of different ASIC channels, including ASIC1a, ASIC2a and ASIC3. However, they did not test the effect of LPC on ASICs and they did not report any activating effect of AA at resting pH7.4. In the present work, we focused on the activating effect of AA and LPC at resting pH7.4. This activating effect of AA/LPC, which must be distinguish from the potentiating effect of the acid-induced current previously described, is specific of ASIC3 channels since the combination of AA+LPC failed to activated ASIC1a, ASIC1b, ASIC2a and ASIC2b channels (Fig.  5B) . However, and as mentioned by the reviewer, these data did not fully demonstrate that specificity is restricted to LPC. We thus performed additional experiments that now show similar results with LPC alone (see new Fig 2E , inset, and results page 7) and confirm the specificity of this lipid for ASIC3 channels. These data therefore further support a role for LPC in patients' exudates.
HEK 293 cells express significant proton-gated currents. This is not the case with CHO cells as in vitro expression system. Do the authors get the same results when they used CHO cells?
==> As suggested by the reviewer, additional experiments have been performed on ASIC3-transfected CHO cells. We now provide new data demonstrating that LPC is also able to activate a constitutive ASIC3 current at resting pH7.4 in this cell line, similarly to what was previously observed in both HEK293 and F-11 cells. These results have been added to the revised manuscript (see new Fig. EV3 and results page 7) .
What is the concentration dependence of the AA and LPC effects? Is the concentration dependence consistent with a binding site on the ASIC3 channel? The authors report an EC50 of 3.8 µM for LPC. It is not obvious how the derived at this number, because the concentration dependence shown in Fig. 3B does not saturate , but is open-ended.
==> Figure 3B shows the dose-response curve for the potentiation of acid-induced ASIC3 current by LPC. This curve was obtained by applying different concentrations of lipid onto patchclamped cells during 1 min. Due to the difficulty to maintain integrity of cells upon application of high concentrations of lipids (>10 µM) for 1 min, it was not possible to reach the maximal effect, and the dose-response curve does not saturate. The EC 50 initially calculated (3.8µM) was therefore underestimated and we have decided to remove this value (see results page 8).
We have now performed additional experiments in order to obtain a dose-response effect for the activation of ASIC3 by LPC at resting pH7.4 (see new Fig. 2D ). In this case, the effect reaches saturation at 10µM, allowing us to determine an EC 50 of 4.3µM for the activating effect of LPC on ASIC3 current (see results page 7). This concentration dependence could be consistent with a binding site on ASIC3 regarding the effective concentration range of already known direct positive modulators of the channel, i. The time dependence of LPC-induced activation is very slow and quite linear over 3 minutes. It does not appear to reach a maximum after 3 minutes as stated by Marra et al.
==> We have included new data at time points over 3 minutes, which confirm that potentiation of the pH7.0-induced ASIC3 current reaches a maximum after 3 minutes (see new Fig.  3A ).
It should be more thoroughly excluded that AA/LPC have indirect effects. Previously it was shown that alkalization (a shift from pH 7 to pH 8) evokes a sustained ASIC3 current. Two arginines are involved in this response. Are the same arginines involved in the AA/LPC response? The AA/LPC binding site(s) should be defined and compared with those for APETx2 and the pH sensor.
==> We agree with the reviewer that it would be interesting to have more evidence for a direct effect of AA/LPC and to know the binding site(s) in ASIC3. However, this is something very challenging, especially because lipids can insert into the plasma membrane and/or directly interact with the channel. In addition, it would be difficult to define these binding site(s) in comparison with those for APETx2 and the pH sensor because (i) the binding site(s) for APETx2 have not been experimentally characterized yet (Baron and Lingueglia, Neuropharmacology 2015,94:19-35) and, (ii) several complementary binding sites for protons (i.e., pH-sensors) have been described in ASIC channels (Jasti et al., Nature 2007,449, 316-323; Paukert et al., JBC 2008, 283, 572-581) . Nevertheless and as suggested by the reviewer, we have tested the effect of LPC on the human ASIC3 double mutant RR68,83GQ. We show that the lipid-mediated activation is lost in this mutant (see Fig. A below) . These new data, which support a contribution of R68 and R83 in the effect of LPC on human ASIC3, may be compatible with a direct effect of lipids on the channel. However, AA/LPC also activates rat ASIC3 channel, which does not contain these two arginines. It thus makes interpretation of the data more difficult and suggests that the mechanism of activation by lipids is probably more complex than just a direct interaction with these two residues. Because we think that these data are not sufficient to directly associate the two arginines with the lipid-induced response, and because it may require more detailed analysis to further explore this possibility, which may be behind the scope of this work, we have decided to not include these data in the revised manuscript.
==> Smith et al. (Neuroscience 2007,145, 686-698) tested the effect of AA on acid-evoked ASIC2a current recorded from inside-out patches. As mentioned by the reviewer, they reported that AA was able to potentiate acid-evoked ASIC2a current from both side of the membrane, but they did not test the effect of LPC. In the present work, we report that LPC is only able to activate ASIC3 in outside-out patches, i.e., from the external side of the membrane. Difference between the data of Smith et al. and our data could suggest differential mechanisms of action of AA and LPC on ASICs. However, data cannot be directly compared because experiments were not performed in the same conditions. Smith et al. tested the potentiating effect of AA on acid-activated ASIC2a current (inside-out patches with pH6.0 solution in the pipette), whereas we tested the activating effect of LPC on ASIC3 channels at resting pH7.4 (inside-out patches with pH7.4 solution in the pipette). Consistently, we did not observed any activation of rat ASIC2a expressed in transfected F-11 cells following application of LPC (see new Fig. 2E ) or co-application of LPC/AA at physiological pH7.4 (Fig. 5B ). This point is now discussed in the revised manuscript (see results page 10). In summary, arachidonic acid has been shown to affect many different ion channels. This may be due to indirect effects on cellular metabolism, protein kinase activities, changes in membrane curvature, and so on. A direct effect of lipid by binding to a site(s) on the channel needs to be shown unequivocally. The results reported in this study are potentially of great physiological relevance, especially in pain research. However, there are too many questions left which need to be answered before the ms may be acceptable for publication. We agree with the reviewer that, even if we favor a direct interaction of lipids with ASIC3, we cannot exclude indirect effects. However, our data are not really compatible with indirect effects for instance on cellular metabolism or protein kinase activities (excised patch-clamp experiments), or changes in membrane curvature (SICM experiments with crenators). Identifying unequivocally the binding site(s) of lipids on the channel is a particularly challenging task, which is illustrated by the complex interpretation of the data obtained from the human ASIC3 arginin double-mutant described above (see Fig. A ). Such analysis may require much more detailed investigations, and is probably beyond the scope of this work. Importantly, this does not question in any way the specificity of the effects that we described here, which has been reinforced in the revised manuscript with regard to the activated channel (see new data showing that the lipid-induced pain in mice is significantly reduced in ASIC3 knockout animals; Fig. 6E ) and to the nature of the agonist (see new data showing the specificity of LPC for ASIC3 channels; Fig 2E) . Thank you for submitting your revised manuscript to The EMBO Journal. Your study has now been seen by two of the original referees (comments included below) and as you will see they both find that all criticisms have been sufficiently addressed. I am therefore happy to inform you that your manuscript can now in principle be accepted for publication with us.
Thank you again for the opportunity to consider your work for publication. I look forward to receiving your final revision
REFEREE REPORTS
The authors have fully addressed my questions in the revised version. I recommend the manuscript should be published in EMBO J and highlighted.
Referee #3:
Deval et al have adequately dealt with criticisms and concerns of the reviewers. They have included additional experiments in their revised version to convincingly show the specificity of lipid activation of ASIC3 channel at neutral pH and its relevance for lipid signalling in painful inflammatory processes.
2nd Revision -authors' response 07 December 2015
Authors made necessary editorial changes.
